Assertion Partly supported AI assessment confidence: 85% certainty 4/5 debate potential 2/5

Tan: GLP-1 medications reduce compulsive behaviors like nail biting and drinking

Garry Tan · Legendary Consumer VC Predicts The Future Of AI Products · Y Combinator · Jun 27, 2025 · at 29:31

Garry Tan (CEO of Y Combinator) and Kirsten Green (Forerunner Ventures) discuss emerging health trends and the second-order behavioral effects of GLP-1 receptor agonists.

0:00 / 0:12exact quote · 12.5s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“One of the weirder things that's happening with GLP-ONEs, I'm sure you're tracking, is that it gives you unbelievable willpower, like people who bite their nails, They stop biting their nails. Or like, people who struggle with alcohol just because they go on a TLT-I.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

GLP-1 medications reduce compulsive behaviors such as nail biting and alcohol dependency.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim bundles two distinct applications of GLP-1 receptor agonists: reducing alcohol dependency/consumption and stopping compulsive behaviors such as nail biting. Peer-reviewed clinical evidence robustly supports the alcohol leg: Phase 2 randomized controlled trials (e.g., JAMA Psychiatry in April 2025, American Journal of Psychiatry in July 2026) and systematic reviews (e.g., Journal of Clinical Medicine in June 2026) have demonstrated statistically significant reductions in heavy drinking days, drinks per drinking day, and cravings among patients with Alcohol Use Disorder. However, the compulsive behavior/nail-biting leg is not clinically substantiated: as of September 2026, reports of cessation of nail biting (onychophagia) and related body-focused repetitive behaviors remain anecdotal or limited to social media surveys, with no completed, peer-reviewed clinical trials demonstrating efficacy.

American Journal of Psychiatry (July 29, 2026): Double-blind Phase 2 RCT showed daily oral semaglutide significantly reduced heavy drinking days (b = -0.580), drinks per drinking day, and alcohol cravings in adults with AUD.
JAMA Psychiatry (April 2025): Phase 2 RCT demonstrated weekly subcutaneous semaglutide reduced drinking outcomes and cravings relative to placebo.
Journal of Clinical Medicine (June 19, 2026): Systematic review of 5 studies (n = 49,892) confirmed significant reductions in alcohol consumption and AUDIT-C scores with GLP-1 agonists.
Research notes confirm no published peer-reviewed clinical trials or interventional studies demonstrate statistically significant efficacy of GLP-1 agonists for nail biting or body-focused repetitive behaviors as of September 2026.

Checked against

[1] nih.gov [2] psychiatry.org [3] ajmc.com [4] youtube.com [5] nih.gov [6] mdedge.com [7] mdpi.com [8] nih.gov

"trichotillomania" "GLP-1" OR "semaglutide" GLP 1 alcohol use disorder clinical trial peer reviewed study semaglutide alcohol consumption randomized controlled trial peer reviewed "nail biting" "semaglutide" clinical trial OR study GLP 1 compulsive behaviors nail biting study semaglutide impulse control body focused repetitive behaviors study

assessed as of 2026-09-05

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

alcohol GLP-ONE

⚑ Spot an error? Report it

More from Garry Tan

Assertion Not checkable as stated

Tan: Returning to Coding with AI Yields 400x Output

“It was 13 years of not coding and then suddenly, boom, I'm doing about 400 X the amount of work that I was that year. The last time I was even sort of like two thirds of the time writing code.”

Garry Tan May 8, 2026 ▶ 1:32 Tokenmaxxing: How Top Builders Use AI To Do The Work Of 400 Engineers · Y Combinator

Prediction Not checkable as stated

Tan predicts everyone on Earth will have a personal AI by 2027

“And then I guarantee you like this time next year, like everyone's going to be saying what you heard here first, which is like every single person on the planet will have their own personal AI.”

Garry Tan May 8, 2026 ▶ 34:25 Tokenmaxxing: How Top Builders Use AI To Do The Work Of 400 Engineers · Y Combinator

Opinion

Garry Tan: Claude in Chrome MCP is among worst software ever used

“Claude in Chrome MCP is one of the worst pieces of software I've ever used. You know, every time it would try to do an action, it would think and think and think. There was crazy context bloat. Often it wouldn't even do anything, but it would take two to three…”

Garry Tan Apr 23, 2026 ▶ 18:28 How to Make Claude Code Your AI Engineering Team · Y Combinator

Opinion

Tan: Artificial general intelligence is literally actually here

“So, you know, there's sort of this explosion in model capability. You know, we've been talking about this for several years, but then it feels like it's here. Like AGI is literally actually here.”

Garry Tan Feb 21, 2026 ▶ 1:14 The AI Agent Economy Is Here · Y Combinator

Opinion

Tan: Harvey and Open Evidence are overcapitalized 'foie gras' startups

“I think they're like, there might be a case of two foie gras startups, like one being Harvey and the other one being open evidence, right?”

Garry Tan Dec 22, 2025 ▶ 26:44 The Truth About The AI Bubble · Y Combinator

Opinion

Garry Tan: Scammy founder programs produce future SBFs and Theranos fraudsters

“I worry that some of these programs are just literally trying to teach people to become more you know, SBFs and Theranos. And that's like, you know, that's a waste of time. Like, and you're going to go to jail.”

Garry Tan Jul 8, 2025 ▶ 21:49 How to Spend Your 20s in the AI Era · Y Combinator

Tan: GLP-1 medications reduce compulsive behaviors like nail biting and drinking

More from Garry Tan

Turn any episode into a week of clips.